Clinovo released a new version of ClinCapture, its advanced open source Electronic Data Capture (EDC) system.
Clinovo released a new version of ClinCapture, its advanced open source Electronic Data Capture (EDC) system. ClinCapture 1.0.3 features new functions including Randomization, Dynamic Groups, and Calendared Events. New advanced features will allow ClinCapture’s users to automate processes, such as event scheduling. ClinCapture 1.0.3 reduces overhead for clinical teams and saves them a significant time in study conduct. ClinCapture has also been complemented with an integrated eClinical Suite introducing height plug-and-play modules including ePRO (Patient Reported Outcome), CTMS (Clinical Trial Management System), and a new offline mode.
ClinCapture 1.0.3 was designed to provide sponsor companies with an extensive and scalable solution to streamline their clinical trials. The system is being utilized on registry studies with more than 20,000 patients over 20 years. “ClinCapture 1.0.3 features an extended set of functions without start-up costs, license fees or vendor lock-in”, explains Ale Gicqueau, President & CEO at Clinovo.
With this new release, ClinCapture becomes the first open source Electronic Data Capture (EDC) system with an integrated randomization capability. Developed in collaboration with Randomize.net, the randomization function performs its role efficiently and seamlessly while preserving data integrity and patient safety. Critical patient data is encrypted throughout the randomization workflow. Randomization time and results are securely logged in the study audit log to ensure 21 CFR Part 11 compliance. The randomization function makes ClinCapture compatible with any clinical studies, involving block, stratified, single- or double-blinded randomization. The randomization function is currently utilized on clinical studies with up to 1,700 patients.
The new Calendared Events and Dynamic Groups functions were designed to automate error-prone and time-consuming processes to reduce overhead and accelerate the study conduct. The new Dynamic Groups function allows sponsor companies to create multiple treatment arms in ClinCapture. Subjects are automatically associated with events related to their treatment arm. The Calendared Events function allows users to automatically schedule events at the completion of a reference event. The function integrates automatic reminder emails when the calendared event is about to begin, and automated queries for missed events according to a pre-defined timeframe. The Calendared Events and Dynamic Groups functions reduce clinical teams’ overhead and streamline study conduct.
ClinCapture’s eClinical Suite extends ClinCapture’s capabilities and meets the needs of medical device and pharmaceutical companies looking to run early and late phase clinical trials or registry studies.
See more at:
http://www.clinovo.com/clinovo-releases-clincapture-103-and-its-new-eclinical-suite#sthash.jvkRLTmR.dpuf
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.